For Biosensors, stents and an acquisition helped drive a stellar year

Singapore device company Biosensors said it generated healthy revenue and profit growth during its 2012 fiscal year, based in part on healthy sales of its Nobori drug eluting stent, licensed by Terumo, for which the company earns licensing revenue. Fully absorbing its purchase of JW Medical Systems and greater sales of interventional cardiology products also helped, the company noted. Biosensors booked $292.1 million in overall revenue during the fiscal year and $88.2 million in fourth quarter revenue, up 72% and 98%, respectively, compared to fiscal 2011. Net profit for the year also reached $101 million and $28.6 million for the quarter. Release

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.